Gender differences in the regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy

Hypertension

Volumn 52, Issue 1, 2008, Pages 59-60

  Agabiti Rosei, Enrico ^a   Salvetti, Massimo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; GLUCOSE; LIPID; LOSARTAN; ANTIHYPERTENSIVE AGENT;

AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BODY COMPOSITION; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; NOTE; OBESITY; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; FEMALE; MALE; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; SEX FACTORS; TREATMENT OUTCOME;

EID: 46449131208     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.111948     Document Type: Note

References (10)

1. de Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertension. 1995;26:979-983.
2. Vakili A, Okin P, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334-341.
3. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and prediction of major cardiovascular events: the LIFE Study. JAMA. 2004;292:2343-2349.
4. Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, Devereux RB, for the Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy. Hypertension. 2008;52:100-106.
5. Gerdts E, Okin PM, de Simone G, Cramariuc D, Wachtell K, Boman K, Devereux RB. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51: 1109-1114.
6. Liao Y, Cooper RS, Mensah GA, Cooper RS, MC Gee DL. Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation. 1995;92:805-810.
7. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille DA, Lyle PA, Okin PM, Dahlöf B, Oparil S. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Lo-sartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51:1103-1108.
8. McEniery C, Yasmin, Hall I, Qasem A, Wilkinson I, Cockcroft J, on behalf of the ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity-the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46: 1753-1760.
9. Hashimoto J, Imai Y, O'Rourke M. Monitoring of antihypertensive therapy for reduction in left ventricular mass. Am J Hypertens. 2007;20: 1229-1233.
10. Kumpusalo E, Lappi J, Miettinen H, Takala J. Prevalence of left ventricular hypertrophy in Finnish primary health care hypertensive patients. J Hum Hypertens. 2001;15:255-258.